NO20003397L - 3 '-epimerie K-252A-derivater - Google Patents

3 '-epimerie K-252A-derivater

Info

Publication number
NO20003397L
NO20003397L NO20003397A NO20003397A NO20003397L NO 20003397 L NO20003397 L NO 20003397L NO 20003397 A NO20003397 A NO 20003397A NO 20003397 A NO20003397 A NO 20003397A NO 20003397 L NO20003397 L NO 20003397L
Authority
NO
Norway
Prior art keywords
epimeric
derivatives
compounds
survival
enhancement
Prior art date
Application number
NO20003397A
Other languages
English (en)
Other versions
NO20003397D0 (no
Inventor
Robert L Hudkins
Diane E Gingrich
Original Assignee
Cephalon Inc
Kyowa Hakko Kogyo Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc, Kyowa Hakko Kogyo Kk filed Critical Cephalon Inc
Publication of NO20003397D0 publication Critical patent/NO20003397D0/no
Publication of NO20003397L publication Critical patent/NO20003397L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Det er omtalt forbindelser som har den angitte generelle struktur (H). Disse forbindelser utviser farmakologiske virkninger, som omfatter inhibisjon av tyrosinkinaseaktivitet og forbedring av funksjonen og/eller overlevelse av trofisk faktor responsive celler, f.eks. cholinerge neuroner.
NO20003397A 1997-12-31 2000-06-29 3 '-epimerie K-252A-derivater NO20003397L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
PCT/US1998/027644 WO1999033836A1 (en) 1997-12-31 1998-12-30 3'-epimeric k-252a derivatives

Publications (2)

Publication Number Publication Date
NO20003397D0 NO20003397D0 (no) 2000-06-29
NO20003397L true NO20003397L (no) 2000-08-31

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003397A NO20003397L (no) 1997-12-31 2000-06-29 3 '-epimerie K-252A-derivater

Country Status (15)

Country Link
US (2) US6093713A (no)
EP (1) EP1044203B1 (no)
JP (1) JP4405667B2 (no)
KR (1) KR20010033737A (no)
CN (1) CN1285836A (no)
AT (1) ATE234308T1 (no)
AU (1) AU1947499A (no)
BR (1) BR9814543A (no)
CA (1) CA2315953C (no)
DE (1) DE69812177T2 (no)
DK (1) DK1044203T3 (no)
ES (1) ES2194385T3 (no)
NO (1) NO20003397L (no)
PT (1) PT1044203E (no)
WO (1) WO1999033836A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60112611T2 (de) * 2000-12-08 2006-06-14 Ortho Mcneil Pharm Inc Makroheterocyclische verbindungen als kinase inhibitoren
CA2446939C (en) * 2001-05-16 2005-08-02 Matthias Stein-Gerlach Pyridylpyrimidine derivatives as effective compounds against prion diseases
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
WO2008076394A1 (en) * 2006-12-14 2008-06-26 Tautatis, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
ATE165097T1 (de) 1993-05-28 1998-05-15 Cephalon Inc Anwendung von indolocarbazol-derivaten zur behandlung von prostataerkrankungen
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
ATE200290T1 (de) * 1994-07-04 2001-04-15 Kyowa Hakko Kogyo Kk Verfahren zur herstellung von indolocarbazol- derivaten
AU6657596A (en) 1995-07-31 1997-02-26 Ciba-Geigy Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
PT1044203E (pt) 2003-07-31
JP4405667B2 (ja) 2010-01-27
DE69812177T2 (de) 2004-01-15
EP1044203B1 (en) 2003-03-12
EP1044203A1 (en) 2000-10-18
BR9814543A (pt) 2000-10-10
KR20010033737A (ko) 2001-04-25
ATE234308T1 (de) 2003-03-15
US6093713A (en) 2000-07-25
JP2001527079A (ja) 2001-12-25
US6451786B1 (en) 2002-09-17
AU1947499A (en) 1999-07-19
DK1044203T3 (da) 2003-07-14
CN1285836A (zh) 2001-02-28
WO1999033836A9 (en) 2000-09-14
DE69812177D1 (de) 2003-04-17
WO1999033836A1 (en) 1999-07-08
ES2194385T3 (es) 2003-11-16
CA2315953C (en) 2010-11-09
CA2315953A1 (en) 1999-07-08
NO20003397D0 (no) 2000-06-29

Similar Documents

Publication Publication Date Title
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
DE69616480T2 (de) Piperidinderivate als neurokininantagonisten
ATE302005T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
WO1992007830A3 (en) Oxindole peptide antagonists
DK0853480T3 (da) Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
ATE302606T1 (de) N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
BR9608789A (pt) Compostos de tetralina com atividade de mdr
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
CA2270964A1 (en) Benzonaphthyridines as bronchial therapeutics
NO985622L (no) Utvalgte derivater av K-252A
NO20003397L (no) 3 '-epimerie K-252A-derivater
FI944014A (fi) Makrolidien desosaminojohdannaiset immuunivastetta heikentävinä aineina ja sieniä vastustavina aineina
DE69322750T2 (de) Dibekacin und Arbekacin Derivate wirksam gegen resistente Bakterien, und ihre Herstellung
TR199701202T1 (xx) Yeni hidroksimik asit t�revleri.
DE69623819T2 (de) Furan- und thiophencarbothioamid derivate, deren herstellung und deren verwendung als inhibitoren der replikation von hiv-1 und hiv-1 mutanten
FI895069A0 (fi) Funktionsanordning av modulkonstruktion foer valsarna i en maskinkalander.
MX9603477A (es) Acido micofenolico 4-amino 6-sustituido y derivados con actividad inmunosupresora.
TR200003580T2 (tr) Farnesil protein transferazı'nın önlenmesine mahsus benzo(5,6)siklohepta(1,2-B)piridin türevleri
ES2082722B1 (es) Procedimiento de preparar 8-(4-(4-(pirimidina-2-il)-piperacina-1-il)-butil)-8-aza-espiro(4.5)decabi-7,9-diona y derivados, asi como los compuestos obtenidos.
IT1247510B (it) Composizioni terapeutiche ad attivita' anti-hiv costituite da 2',3'-didesossiadenosina e sostanze inibitrici della adenosina-deaminasi
NO20016326L (no) Anvendelse av proteinet UK 114 for å hindre avstötning av organtransplantatet
MX9603483A (es) Acido micofenolico 6-sustituido y derivados.
DE59809929D1 (de) 6-substituierte 1,2,4a,5a,8a,8b-hexahydro- und 1,2,3,4,4a,5a,8a,8b-oktahydro-6h-pyrrolo[3',4':4,5]furo[3,2-b]pyrid-8(7h)-on derivate und ihre verwendung zur bekämpfung von endoparasiten
NO168544C (no) Sperreelement for gangvei, saerlig for aa hindre adkomst avpersonbiler i gangveien.
MX9706968A (es) Compuesto de tiocarbamoilo.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application